ArticleWorld journal of microbiology & biotechnology2025
Isolation and structure determination of a new antibacterial lanthipeptide derived from the marine derived bacterium Lysinibacillus sp.CTST325.
Article in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sulfur-Containing Microbial Natural Products and Their Role in Communal Interactions.Journal of natural products · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Marine resources are attractive for screening new useful bacteria. From a marine sediment sample, we performed isolation and screening of bacterial strains in search of new bioactive compounds. HPLC and ESI-MS analysis indicated that the new bacterium, Lysinibacillus sp. CTST325 (NBRC 116944), produced a new peptidic compound, lysinibacin. Genome sequence analysis of Lysinibacillus sp. CTST325 indicated the presence of several biosynthetic gene clusters for secondary metabolites, including lanthipeptides. The structure determination of lysinibacin was performed using CID-MS and NMR spectral data. As a result, lysinibacin was identified as a new class III lanthipeptide, containing N-dimethylated Tyr at the N-terminus and the unusual amino acid labionin at the C-terminus. The biosynthetic gene cluster of lysinibacin was identified from the genome data of the strain CTST325, based on the structure of lysinibacin. Lysinibacin showed antibacterial activity against Gram-positive bacteria.
Indexed as
Identifiers
39878791What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.